Expert Outlook: Dentsply Sirona Through The Eyes Of 9 Analysts
In the preceding three months, 9 analysts have released ratings for Dentsply Sirona (NASDAQ:XRAY), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 3 | 4 | 1 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 1 | 0 | 0 |
| 2M Ago | 0 | 1 | 1 | 1 | 0 |
| 3M Ago | 0 | 1 | 2 | 0 | 0 |
Analysts have recently evaluated Dentsply Sirona and provided 12-month price targets. The average target is $13.33, accompanied by a high estimate of $16.00 and a low estimate of $12.00. This current average represents a 10.42% decrease from the previous average price target of $14.88.
Decoding Analyst Ratings: A Detailed Look
The perception of Dentsply Sirona by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Kevin Caliendo | UBS | Lowers | Buy | $16.00 | $17.00 |
| Steven Valiquette | Mizuho | Raises | Neutral | $14.00 | $13.00 |
| Michael Petusky | Barrington Research | Maintains | Outperform | $14.00 | $14.00 |
| Michael Petusky | Barrington Research | Maintains | Outperform | $14.00 | $14.00 |
| Jeffrey Johnson | Baird | Lowers | Neutral | $12.00 | $14.00 |
| Glen Santangelo | Barclays | Announces | Underweight | $12.00 | - |
| Michael Petusky | Barrington Research | Lowers | Outperform | $14.00 | $18.00 |
| Lilia-Celine Lozada | JP Morgan | Lowers | Neutral | $12.00 | $14.00 |
| Vik Chopra | Wells Fargo | Lowers | Equal-Weight | $12.00 | $15.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Dentsply Sirona. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Dentsply Sirona compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Dentsply Sirona's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Dentsply Sirona's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Dentsply Sirona analyst ratings.
About Dentsply Sirona
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is sold to labs and offices through the firm's salesforce or directly to consumers (such as the Byte clear aligner).
Dentsply Sirona: A Financial Overview
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Decline in Revenue: Over the 3M period, Dentsply Sirona faced challenges, resulting in a decline of approximately -4.94% in revenue growth as of 30 September, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -47.23%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Dentsply Sirona's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -24.84%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.29%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.68.
The Significance of Analyst Ratings Explained
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.